Non-disclosure probe
This article was originally published in The Gray Sheet
Executive Summary
Spine surgeon Jeffrey Wang has been removed from his role as co-executive director of the University of California, Los Angeles Comprehensive Spine Center, while an independent committee at the UCLA medical school conducts an internal investigation into Wang's failure to disclose consulting fees and stock option arrangements with device firms including Johnson & Johnson/DePuy Spine, Medtronic and Facet Solutions. The committee will determine if the conflicts of interest interfered with research and what "mitigating actions" are needed. UCLA also responded to inquiries about the non-disclosures from Sen. Charles Grassley, R-Iowa, co-author of the Physician Payments Sunshine Act
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.